Skip to main content
. 2022 Nov 7;14(21):5472. doi: 10.3390/cancers14215472

Figure 1.

Figure 1

Role of HDAC1 in different signaling pathways involved in GC progression. HDAC1 promotes GC cell proliferation via lncRNA HRCEG repression, lncRNAs BC01600 and AF116637 upregulation, or MORC2/p21 pathway. HDAC1 favors metastatic abilities of GC cells through miR-34a repression inducing CD44 expression. HDAC1 promotes HIF-1α activity leading to glycolysis in GC cells. HDAC1 inhibits CRADD transcription and consequently caspase-2-dependent apoptosis. HDAC1 is a resistance factor to chemotherapies in GC such as anthracycline, via repression of CITED2, and doxorubicin, inhibiting its fixation on DNA. Figure has been generated using Biorender (Biorender.com).